Oct. 8, 2009 (Business Wire) — Vivakor, Inc. (OTCBB: VIVK) announces distribution of its VivaThermic products to the rapidly growing biotech/biopharma industries in India through its agreement with Pro Lab Marketing Pvt. Ltd. This agreement gives Pro Lab Marketing distribution rights for Vivakor’s VivaThermic cryovials in India. Pro Lab Marketing, based in New Delhi, is a well-established Indian supplier of biotechnology-related products and equipment throughout India. “We are impressed with the VivaThermic products and their outstanding performance,” stated Mr. J.K. Jain, Managing Director of Pro Lab Marketing. He continues, “Through our distribution agreement with Vivakor we will introduce the VivaThermic products to our customers throughout India who will benefit greatly from use of this technology.”

Vivakor’s CEO, Dr. Tannin Fuja, indicated that, “The Indian biotechnology industry is gaining significant momentum and India figures to become a prominent player in the global biotech market. A number of India’s biotech firms

Dynavax Technologies Corp. (DVAX) is a biopharmaceutical company focused on drug development for the treatment and prevention of various infectious and inflammatory diseases.

The company was recently hit hard by a couple of major negative events: the clinical hold and the subsequent termination of the partnership with Merck (MRK) for Heplisav, a late stage candidate for Hepatitis B vaccine, and the discontinuation of the Tolamba program for allergy. Currently, Dynavax is in active discussions with regulatory agencies to resolve the FDA's clinical hold on Heplisav and identify an appropriate path for its further development and approval in the United States, Europe, and the rest of the world.

The deal with Glaxo is a big positive

In 4Q08, Dynavax and GlaxoSmithKline (GSK) signed a worldwide strategic alliance to discover, develop and commercialize novel inhibitors of endosomal Toll-like Receptors (TLRs) for the treatment of immuno-inflammatory diseases.